UPDATE: Oppenheimer Starts Fulcrum Therapeutics (FULC) at Outperform
Tweet Send to a Friend
(Updated - March 7, 2022 4:03 PM EST)
Oppenheimer analyst Matthew Biegler initiates coverage on Fulcrum Therapeutics (NASDAQ: FULC) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Matthew Biegler initiates coverage on Fulcrum Therapeutics (NASDAQ: FULC) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
